Seven Eight Capital LP Acquires 158,358 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Seven Eight Capital LP increased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 1,407.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 169,612 shares of the biotechnology company's stock after buying an additional 158,358 shares during the period. Seven Eight Capital LP owned 0.08% of BioCryst Pharmaceuticals worth $1,048,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. CWM LLC grew its holdings in shares of BioCryst Pharmaceuticals by 200.0% during the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 3,772 shares in the last quarter. Signaturefd LLC grew its stake in BioCryst Pharmaceuticals by 560.5% during the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company's stock worth $41,000 after buying an additional 5,599 shares in the last quarter. Quarry LP bought a new position in BioCryst Pharmaceuticals in the 4th quarter valued at about $54,000. nVerses Capital LLC acquired a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at approximately $63,000. Finally, Natixis lifted its holdings in shares of BioCryst Pharmaceuticals by 400.6% during the 1st quarter. Natixis now owns 11,684 shares of the biotechnology company's stock worth $59,000 after acquiring an additional 9,350 shares during the period. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Stock Down 0.5 %

BioCryst Pharmaceuticals stock traded down $0.04 during trading hours on Friday, hitting $8.11. The stock had a trading volume of 3,631,767 shares, compared to its average volume of 3,143,513. The business's 50 day simple moving average is $7.79 and its 200-day simple moving average is $6.35. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -7.58 and a beta of 1.88. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.11. The business had revenue of $109.30 million during the quarter, compared to analyst estimates of $98.30 million. During the same quarter last year, the company posted ($0.24) earnings per share. The company's revenue was up 34.9% compared to the same quarter last year. Research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.45 EPS for the current fiscal year.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, Director Amy E. Mckee sold 8,600 shares of the company's stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $6.32, for a total value of $54,352.00. Following the sale, the director now owns 27,831 shares in the company, valued at approximately $175,891.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.80% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on BCRX. JMP Securities lifted their price objective on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a "market outperform" rating in a research note on Tuesday, August 6th. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. Barclays boosted their target price on BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the stock an "equal weight" rating in a research note on Tuesday, August 6th. Finally, StockNews.com upgraded shares of BioCryst Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Tuesday, August 6th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $14.17.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.